HERCULES, CA--(MARKET WIRE)--Oct 2, 2007 -- Bio-Rad Laboratories, Inc. (AMEX:BIO - News) and (AMEX:BIO-B - News), a multinational manufacturer and distributor of life science research and clinical diagnostics products, announced today that it has completed the purchase of approximately 77.7% of the outstanding shares of DiaMed Holding AG for approximately 477 million Swiss francs. Bio-Rad entered into a definitive agreement to acquire these shares in May of this year. The transaction was subject to certain closing conditions, including regulatory approvals. DiaMed holds approximately 9.6% of its out-standing shares as treasury shares. Bio-Rad will conduct a tender offer to acquire the remaining 12.7% outstanding shares within the next 12 months.
